- Molecular NameSumatriptan
- SynonymNP101; sumatriptan; Sumatriptan Succinate; Sumatriptanum [INN-Latin]; triptan
- Weight295.407
- Drugbank_IDDB00669
- ACS_NO103628-46-2
- Show 2D model
- LogP (experiment)0.93
- LogP (predicted, AB/LogP v2.0)1.32
- pka9.5
- LogD (pH=7, predicted)-0.31
- Solubility (experiment)21.4 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.42
- LogSw (predicted, AB/LogsW2.0)1.99
- Sw (mg/ml) (predicted, ACD/Labs)0.78
- No.of HBond Donors2
- No.of HBond Acceptors5
- No.of Rotatable Bonds6
- TPSA73.58
- StatusFDA approved
- AdministrationTablet, subcutaneous injection, nasal spray
- PharmacologyA triptan drug including a sulfonamide group for the treatment of migraine headaches.
- Absorption_value67.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability14.0
- Protein binding17.5
- Volume of distribution (VD)0.65 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmSumatriptan is metabolised primarily by monoamine oxidase A into an indole acetic acid analogue, part of which is further conjugated with glucuronic acid.
- Half life1.0 h (An apparent t1/2 of 2 hours reported for SC and oral doses)
- Excretion60% urine; 40% feces
- Urinary Excretion22
- Clerance22 ml/min/kg
- ToxicitySymptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.
- LD50 (rat)N/A
- LD50 (mouse)N/A